Teva Pharmaceutical Industries (NYSE:TEVA) reported first-quarter 2026 results that management said reflected continued ...

Teva exceeded all sustainability-linked bond targets, linking financial performance to expanded patient access to medicines ...

Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million | Teva Pharmaceuticals has struck a deal to ...

For an accessible version of this Press Release, please visit Q1 2026 revenues of ~$4.0 billion increased by 2% in U.S.

On April 29, 2026, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced entering into a definitive agreement to ...

The Federal Circuit recently clarified its written description jurisprudence concerning claims directed to methods of using a ...

Blackstone committed $400 million to fund development of Teva's promising autoimmune disease drug duvakitug. This deal ...

Teva Pharmaceutical Industries (NYSE: TEVA) will unveil its first-quarter results this Wednesday, April 29. Many Teva ...

Teva (TEVA) stock jumps as the company exceeds forecasts with Q1 2026 financials. However, it cut its 2026 earnings outlook ...

This deal falls under Teva’s wider strategy to prioritise strategic, financially diligent deals around de-risked, ...

Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology ...

After a hiatus of almost a decade, Teva has made a pipeline-building acquisition, buying Emalex Biosciences and its candidate ...